370 related articles for article (PubMed ID: 25678112)
1. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
2. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Yalcin TE; Ilbasmis-Tamer S; Takka S
Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
5. HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers.
Lin C; Hu Z; Yuan G; Su H; Zeng Y; Guo Z; Zhong F; Jiang K; He S
J Drug Target; 2019 Aug; 27(7):797-805. PubMed ID: 30481072
[TBL] [Abstract][Full Text] [Related]
6. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
7. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Li J; Chen Y; Zeng L; Lian G; Chen S; Li Y; Yang K; Huang K
J Biomed Nanotechnol; 2016 Aug; 12(8):1654-66. PubMed ID: 29342344
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
9. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer.
Ray P; Ferraro M; Haag R; Quadir M
Macromol Biosci; 2019 Jul; 19(7):e1900073. PubMed ID: 31183964
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
11. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
12. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.
Yu X; Di Y; Xie C; Song Y; He H; Li H; Pu X; Lu W; Fu D; Jin C
Int J Nanomedicine; 2015; 10():6825-34. PubMed ID: 26586944
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Tang S; Hang Y; Ding L; Tang W; Yu A; Zhang C; Sil D; Xie Y; Oupický D
Mol Pharm; 2021 Dec; 18(12):4448-4458. PubMed ID: 34699242
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
